Niagen Bioscience, Inc.
NAGE
$3.17
$0.041.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -5.37% | -6.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.37% | -6.99% | |||
| Cost of Revenue | -8.93% | -5.25% | |||
| Gross Profit | -3.31% | -7.96% | |||
| SG&A Expenses | 1.08% | -5.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.72% | -5.79% | |||
| Operating Income | -55.58% | -25.06% | |||
| Income Before Tax | -84.13% | 52.24% | |||
| Income Tax Expenses | -74.58% | 42.81% | |||
| Earnings from Continuing Operations | -84.76% | 52.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -84.76% | 52.90% | |||
| EBIT | -55.58% | -25.06% | |||
| EBITDA | -46.92% | -18.90% | |||
| EPS Basic | -84.70% | 51.24% | |||
| Normalized Basic EPS | -45.10% | -20.73% | |||
| EPS Diluted | -85.71% | 38.61% | |||
| Normalized Diluted EPS | -43.75% | -20.44% | |||
| Average Basic Shares Outstanding | -0.74% | 1.20% | |||
| Average Diluted Shares Outstanding | -2.44% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||